Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier

Abstract : Purpose: The objective of the current study was to determine the ability of some antiemetic compounds to cross the blood-brain barrier (BBB) and thereby to determine possible side effects of compounds for the central nervous system (CNS). Methods: We compared the brain penetration of some antiemetic compounds using an in vitro BBB model consisting in brain capillary endothelial cells co-cultured with primary rat glial cells. Results: This study clearly demonstrated that the metopimazine metabolite, metopimazine acid, has a very low brain penetration, lower than metopimazine and even less than the other antiemetic compounds tested in this study. Conclusions: The poor brain penetration of metopimazine acid, metopimazine biodisponible form, seems very likely related to the clinically observed difference in therapeutic and safety profile.
Type de document :
Article dans une revue
Pharmacological Research, Elsevier, 2007, 56, p. 11-17
Liste complète des métadonnées

https://hal-univ-artois.archives-ouvertes.fr/hal-00543519
Contributeur : Wilfried Déplanques <>
Soumis le : lundi 6 décembre 2010 - 13:56:25
Dernière modification le : lundi 6 décembre 2010 - 13:56:25

Identifiants

  • HAL Id : hal-00543519, version 1

Collections

Citation

Pascale Jolliet-Riant, Stéphane Nion, Gwenaëlle Allain-Veyrac, Laurence Tilloy-Fenart, Dorothée Vanuxeem, et al.. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacological Research, Elsevier, 2007, 56, p. 11-17. 〈hal-00543519〉

Partager

Métriques

Consultations de la notice

124